Clinical Trials Directory

Trials / Sponsors / Allena Pharmaceuticals

Allena Pharmaceuticals

Industry · 12 registered clinical trials.

StatusTrialPhaseStarted
TerminatedPhase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney
Hyperuricemia, Gout, Chronic Kidney Diseases
Phase 22022-09-02
CompletedScintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
Hyperuricemia, Gout
Phase 12022-01-11
CompletedAn Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
Hyperuricemia, Gout, Chronic Kidney Diseases
Phase 22021-07-16
CompletedStudy 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Hyperuricemia, Gout
Phase 12021-04-21
CompletedALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
Hyperuricemia
Phase 12020-09-02
TerminatedEstablishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Enteric Hyperoxaluria
Phase 32019-08-26
CompletedStudy of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Enteric Hyperoxaluria, Primary Hyperoxaluria, Hyperoxalemia
Phase 22018-07-17
CompletedEvaluate ALLN-177 in Patients With Enteric Hyperoxaluria
Enteric Hyperoxaluria
Phase 32018-05-21
CompletedA Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria
N/A2016-11-01
CompletedEvaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidne
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria
Phase 22015-09-01
CompletedEvaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones
Phase 22015-07-01
CompletedEvaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hypero
Hyperoxaluria, Nephrolithiasis
Phase 22014-09-01